Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Council approves two senior appointments
2012-03-13

 

Dr Choice Makhetha and Prof. Hendri Kroukamp
13 March 2012

 

We are delighted to announce the appointment of Dr Choice Makhetha as Vice-Rector: External Relations, and Prof. Hendri Kroukamp as Dean of the Faculty of Economic and Management Sciences.

Both appointments were approved on Friday 9 March 2012 by the UFS Council during its quarterly meeting at the Bloemfontein Campus.
 
“Dr Makhetha is an experienced administrator in higher education and has spent time shadowing the Presidents of Harvard and Spelman Universities in the USA, where she gained invaluable experience in positioning universities for world-class impact,” said Prof. Jonathan Jansen, Vice-Chancellor and Rector of the UFS.
Her portfolio will entail external linkages, partnerships and strategic alliances of the university with national and international stakeholders.
Previously, Dr Makhetha was the Special Assistant to the Vice-Chancellor. Before that she was acting Dean: Student Affairs, also at the UFS. She has served as acting Vice-Rector: External Relations since February 2011.  
 
Dr Makhetha obtained a Master’s degree in Political Science from the UFS in 2000 and a Ph.D., also in Political Science, in 2003. She was named the UFS’s Dux student for 1998/99. Dr Makhetha has received many awards for her work and she serves on various boards and committees in South Africa and abroad.
 
In 2010 and 2011 she was a fellow at Harvard University and Spelman College as part of Higher Education South Africa (HESA)’s Higher Education Leadership and Management programme.
 
“Prof. Kroukamp is a distinguished academic in the field of Public Administration and a highly experienced manager and leader of academic departments. He has been serving as acting Dean of his faculty since September 2010,” said Prof. Jansen.
 
Prof. Kroukamp holds a B.A. (Hons.) degree in Public Administration from Stellenbosch University and an M.A. degree from the University of Port Elizabeth (UPE). In 1993 he obtained a qualification in Project Management from the World Bank. He completed a D.Phil. in Public Administration at UPE in 1996, where he was a lecturer. Prof. Kroukamp joined the UFS in 1999 as a professor and Chairperson of the Department of Public Management.
 
He is the referee of various national and international publications, serves on various publication boards and is a member of various national and international boards and committees.
 
Prof. Kroukamp, who is a National Research Foundation (NRF)-rated researcher, has received many NRF awards. Amongst these are NRF Overseas International Conference Awards in Turkey, Korea, Poland and France. He has also received a UFS Top Research Award in the Faculty of Economic and Management Sciences.
 
Both appointments apply retrospectively on 1 March 2012.
 

Media Release
13 March 2012
Issued by: Lacea Loader
Director: Strategic Communication
Tel: +27(0)51 401 2584
Cell: +27(0)83 645 2454
E-mail: news@ufs.ac.za

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept